Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2022.09.08

Sai Life Sciences Manchester announces recruitment drive to increase scientific team by 20%

Sai Life Sciences Manchester announces recruitment drive to increase scientific team by 20%

Commences recruitment for 15 positions across analytical, chemistry, engineering and particle sciences departments

Sai Life Sciences, today announced plans to grow the scientific team at its site in Manchester, UK by 20% and commenced the process of recruitment for 15 positions across analytical, chemistry, engineering and particle sciences departments. View open positions.

Making the announcement, Dr Dean Edney, Global Head of Process R&D at Sai Life Sciences said, “In a little over two years since we began in Manchester, our team has established a formidable reputation for itself as a high-quality scientific unit that can solve complex chemistry challenges. Our growing list of global innovator clients is a strong validation of our success. The present recruitment drive is aimed at increasing our scientific capacity to better serve the growing demand.”

In July 2020, Sai Life Sciences opened a new Centre of Excellence in Process Chemistry R&D in Alderley Park, Manchester to help accelerate the NCE development programmes of its global innovator customers. This Centre has since grown to become a reliable partner to many innovator companies across the world, providing high quality chemistry, non-GMP material delivery, and successful technology transfer to its sites in India for scale-up.

Now, with a growing interest from its customers for clinical API supplies from Manchester, work is underway to set-up a GMP Kilo Lab at the Manchester site. Scheduled to be commissioned in Q4-2022, the new facility will be capable of delivering GMP drug substance and intermediates, with the GMP equipment engineered to provide containment down to 1µg/m3.

As part of the SaiNxt transformation initiative, the company has executed investments of US$110M in expanding into new geographies, augmenting its capacity and operations, while raising the bar for quality, compliance and performance.

Share article

More News

2025.10.08

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators

Manchester/Hyderabad, October 08, 2025: Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API […]
Read more

2025.10.06

Unlocking Chemical Frontiers: IIT Bombay Prof, Debabrata Maiti at Sai Life Sciences

As part of Sai Life Sciences’ efforts to foster knowledge exchange and bring leading voices from niche areas of science and technology to its teams, the company recently hosted Prof. Debabrata Maiti from the Indian Institute of Technology (IIT) Bombay at its R&D campus in Hyderabad for a day of scientific exchange and dialogue. The […]
Read more

2025.09.18

Sai Life Sciences opens dedicated facility for Veterinary APIs in Bidar, India

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for veterinary API production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. The new […]
Read more

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more